{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:47:14Z","timestamp":1773359234030,"version":"3.50.1"},"reference-count":44,"publisher":"BMJ","issue":"9","funder":[{"name":"Heart Foundation of Northern Sweden"},{"DOI":"10.13039\/501100002960","name":"V\u00e4sterbotten L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effect of antihypertensive treatment in the 130\u2013140\u2009mm Hg systolic blood pressure range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Information sources<\/jats:title>\n                    <jats:p>PubMed, CDSR and DARE were searched for the systematic reviews, which were manually browsed for clinical trials. PubMed and Cochrane Central Register of Controlled Trials were searched for trials directly in February 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Randomised double-blind trials with \u22651000 patient-years of follow-up, comparing any antihypertensive agent against placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and risk of bias<\/jats:title>\n                    <jats:p>Two reviewers extracted study-level data, and assessed risk of bias using Cochrane Collaborations risk of bias assessment tool, independently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>Primary outcomes were all-cause mortality, major cardiovascular events and discontinuation due to adverse events. Secondary outcomes were cardiovascular mortality, myocardial infarction, stroke, heart failure, hypotension-related adverse events and renal impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen trials, including 92 567 participants (34% women, mean age 63 years), fulfilled the inclusion criteria. Primary preventive antihypertensive treatment was associated with a neutral effect on all-cause mortality (relative risk 1.00, 95% CI 0.95 to 1.06) and major cardiovascular events (1.01, 0.96 to 1.06), but an increased risk of discontinuation due to adverse events (1.23, 1.03 to 1.47). None of the secondary efficacy outcomes were significantly reduced, but the risk of hypotension-related adverse events increased with treatment (1.71, 1.32 to 2.22). In coronary artery disease secondary prevention, antihypertensive treatment was associated with reduced risk of all-cause mortality (0.91, 0.83 to 0.99) and major cardiovascular events (0.85, 0.77 to 0.94), but doubled the risk of adverse events leading to discontinuation (2.05, 1.62 to 2.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Primary preventive blood pressure lowering in the 130\u2013140\u2009mm Hg systolic blood pressure range adds no cardiovascular benefit, but increases the risk of adverse events. In the secondary prevention, benefits should be weighed against harms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42018088642.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-026686","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:15:12Z","timestamp":1569917712000},"page":"e026686","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-0905","authenticated-orcid":false,"given":"Mattias","family":"Brunstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Carlberg","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2025121400381981000_9.9.e026686.1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMra1510067","article-title":"Lessons in Uncertainty and Humility - Clinical Trials Involving Hypertension","volume":"375","author":"Pfeffer","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121400381981000_9.9.e026686.2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000065"},{"key":"2025121400381981000_9.9.e026686.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"2025121400381981000_9.9.e026686.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"2025121400381981000_9.9.e026686.5","doi-asserted-by":"crossref","unstructured":"Whelton PK , Carey RM , Aronow WS , et al . 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American heart association Task force on clinical practice guidelines. Hypertension;2017.","DOI":"10.1161\/HYP.0000000000000065"},{"key":"2025121400381981000_9.9.e026686.6","unstructured":"Williams B , Mancia G , et al . ESC\/ESH hypertension guidelines. J Hypertens. In Press 2018."},{"key":"2025121400381981000_9.9.e026686.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"2025121400381981000_9.9.e026686.8","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1161\/HYP.0000000000000067","article-title":"Systematic review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American heart association Task force on clinical practice guidelines","volume":"71","author":"Reboussin","year":"2018","journal-title":"Hypertension"},{"key":"2025121400381981000_9.9.e026686.9","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Green S , Cochrane Collaboration . Cochrane Handbook for systematic reviews of interventions. Chichester, West Sussex; Hoboken NJ: Wiley-Blackwell, 2008.","DOI":"10.1002\/9780470712184"},{"key":"2025121400381981000_9.9.e026686.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-6-201209180-00537"},{"key":"2025121400381981000_9.9.e026686.11","doi-asserted-by":"crossref","unstructured":"Liberati A , Altman DG , Tetzlaff J , et al . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339.doi:10.1136\/bmj.b2700","DOI":"10.1136\/bmj.b2700"},{"key":"2025121400381981000_9.9.e026686.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs104"},{"key":"2025121400381981000_9.9.e026686.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs215"},{"key":"2025121400381981000_9.9.e026686.14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstr\u00f6m","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025121400381981000_9.9.e026686.15","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Altman DG , Gotzsche PC , et al . The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343.doi:10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"2025121400381981000_9.9.e026686.16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/HJH.0000000000001574","article-title":"Standardization according to blood pressure lowering in meta-analyses of antihypertensive trials: comparison of three methodological approaches","volume":"36","author":"Brunstr\u00f6m","year":"2018","journal-title":"J Hypertens"},{"key":"2025121400381981000_9.9.e026686.17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380"},{"key":"2025121400381981000_9.9.e026686.18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (action trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"The Lancet"},{"key":"2025121400381981000_9.9.e026686.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008816"},{"key":"2025121400381981000_9.9.e026686.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208799"},{"key":"2025121400381981000_9.9.e026686.21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.13.1721"},{"key":"2025121400381981000_9.9.e026686.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065061"},{"key":"2025121400381981000_9.9.e026686.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"2025121400381981000_9.9.e026686.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"2025121400381981000_9.9.e026686.25","unstructured":"Lonn EM , Bosch J , L\u00f3pez-Jaramillo P , et al . Blood-Pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016."},{"key":"2025121400381981000_9.9.e026686.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"2025121400381981000_9.9.e026686.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001121"},{"key":"2025121400381981000_9.9.e026686.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00736-1"},{"key":"2025121400381981000_9.9.e026686.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042739"},{"key":"2025121400381981000_9.9.e026686.30","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282ff8864"},{"key":"2025121400381981000_9.9.e026686.31","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000146378.65439.7A"},{"key":"2025121400381981000_9.9.e026686.32","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","article-title":"Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial","volume":"128","author":"Ravid","year":"1998","journal-title":"Ann Intern Med"},{"key":"2025121400381981000_9.9.e026686.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007994"},{"key":"2025121400381981000_9.9.e026686.34","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.15.1748"},{"key":"2025121400381981000_9.9.e026686.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154"},{"key":"2025121400381981000_9.9.e026686.36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"The Lancet"},{"key":"2025121400381981000_9.9.e026686.37","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000881"},{"key":"2025121400381981000_9.9.e026686.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.02.038"},{"key":"2025121400381981000_9.9.e026686.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.045"},{"key":"2025121400381981000_9.9.e026686.40","doi-asserted-by":"crossref","unstructured":"Brunstr\u00f6m M , Carlberg B . Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352.doi:10.1136\/bmj.i717","DOI":"10.1136\/bmj.i717"},{"key":"2025121400381981000_9.9.e026686.41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"2025121400381981000_9.9.e026686.42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.18574"},{"key":"2025121400381981000_9.9.e026686.43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","article-title":"Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials","volume":"6","author":"Beddhu","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121400381981000_9.9.e026686.44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.ajkd.2017.08.021","article-title":"Effects of intensive blood pressure treatment on acute kidney injury events in the systolic blood pressure intervention trial (SPRINT)","volume":"71","author":"Rocco","year":"2018","journal-title":"Am J Kidney Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-026686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:38:32Z","timestamp":1765701512000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-026686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bmjopen-2018-026686"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-026686","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}